Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M10,136Revenue $M872Net Margin (%)3.0Z-Score3.7
Enterprise Value $M10,902EPS $3.5Operating Margin %14.8F-Score5
P/E(ttm))393Cash Flow Per Share $3.6Pre-tax Margin (%)11.5Higher ROA y-yN
Price/Book7.710-y EBITDA Growth Rate %0Quick Ratio3.8Cash flow > EarningsY
Price/Sales9.55-y EBITDA Growth Rate %68.1Current Ratio3.9Lower Leverage y-yN
Price/Cash Flow14.2y-y EBITDA Growth Rate %-30.1ROA % (ttm)1.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)2.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M60.5ROI % (ttm)19.6Gross Margin Increase y-yY

Gurus Latest Trades with JAZZ

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JAZZSteve Mandel 2014-09-30 Reduce-0.17%$132.55 - $174.37
($153.67)
$ 169.8810%Reduce -14.3%1,788,607
JAZZNWQ Managers 2014-09-30 Reduce-0.1%$132.55 - $174.37
($153.67)
$ 169.8810%Reduce -32.97%138,705
JAZZGeorge Soros 2014-06-30 Sold Out $124.63 - $154.82
($138.55)
$ 169.8823%Sold Out0
JAZZSteve Mandel 2014-06-30 Reduce-0.15%$124.63 - $154.82
($138.55)
$ 169.8823%Reduce -10.98%2,087,127
JAZZJoel Greenblatt 2014-06-30 Sold Out -0.02%$124.63 - $154.82
($138.55)
$ 169.8823%Sold Out0
JAZZSteve Mandel 2014-03-31 Buy 1.4%$125.51 - $174.98
($149.95)
$ 169.8813%New holding, 2344486 sh.2,344,486
JAZZNWQ Managers 2014-03-31 Add0.04%$125.51 - $174.98
($149.95)
$ 169.8813%Add 26.81%173,919
JAZZJoel Greenblatt 2014-03-31 Buy 0.02%$125.51 - $174.98
($149.95)
$ 169.8813%New holding, 7367 sh.7,367
JAZZGeorge Soros 2014-03-31 Buy $125.51 - $174.98
($149.95)
$ 169.8813%New holding, 3600 sh.3,600
JAZZJohn Paulson 2013-12-31 Sold Out -0.57%$82.62 - $126.79
($103.31)
$ 169.8864%Sold Out0
JAZZNWQ Managers 2013-12-31 Reduce-0.05%$82.62 - $126.79
($103.31)
$ 169.8864%Reduce -29.02%137,154
JAZZNWQ Managers 2013-06-30 Buy 0.12%$52.79 - $70.86
($61.12)
$ 169.88178%New holding, 198679 sh.198,679
JAZZJohn Paulson 2012-09-30 Buy 0.47%$44.4 - $58.5
($48.28)
$ 169.88252%New holding, 1000000 sh.1,000,000
JAZZKen Heebner 2011-12-31 Sold Out -0.09%$34.8 - $44.27
($38.53)
$ 169.88341%Sold Out0
JAZZKen Heebner 2011-09-30 Buy 0.09%$32.7 - $46.8
($39.51)
$ 169.88330%New holding, 95000 sh.95,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JAZZ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JAZZ Steve Mandel 2014-09-301,788,6072.961.1-14.3%
JAZZ NWQ Managers 2014-09-30138,7050.230.24-32.97%
Premium Most recent portfolio changes are included for Premium Members only!


JAZZ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ENRIGHT PATRICK GDirector 2014-12-12Sell2,343$170.98-2.68view
Hooper Suzanne SawochkaEVP and General Counsel 2014-12-09Sell1,852$178.79-6.93view
COZADD BRUCE CChairman and CEO 2014-12-09Sell5,000$178.79-6.93view
ENRIGHT PATRICK GDirector 2014-12-01Sell10,000$172.74-3.67view
Tobias Jeffrey KEVP, Research & Dev and CMO 2014-11-24Sell4,598$170.12-2.19view
Tobias Jeffrey KEVP, Research & Dev and CMO 2014-11-14Sell1,000$173.32-3.99view
COZADD BRUCE CChairman and CEO 2014-11-11Sell5,000$173.63-4.16view
Hooper Suzanne SawochkaEVP and General Counsel 2014-11-11Sell1,852$173.63-4.16view
ENRIGHT PATRICK GDirector 2014-11-10Sell10,000$171.09-2.74view
McGill IainHead of EUSA Int'l & SVP 2014-11-07Sell7,066$172.03-3.27view

Press Releases about JAZZ :

    Quarterly/Annual Reports about JAZZ:

    News about JAZZ:

    Articles On GuruFocus.com
    Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
    Growth Momentum Should Continue For This Pharmaceutical Company Nov 15 2014 
    Jazz Pharmaceuticals: Growth Trajectory Can Continue In Future Sep 03 2014 
    Weekly CFO Sells Highlight: Google Inc, Jazz Pharmaceuticals PLC, Jack in the Box Inc. Jun 30 2014 
    Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI Mar 11 2014 
    Weekly CFO Sells Highlight: Jazz Pharmaceuticals PLC, Carnival PLC, Juniper Networks Inc., Home Depo Mar 10 2014 
    comment on JAZZ Mar 21 2013 
    optimized portfolio Jul 26 2011 
    Jazz Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 08 2011 
    Jazz Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 


    More From Other Websites
    Equity markets surge...so many stories – where to begin? Dec 17 2014
    Stocks Close Near Session Lows And Down For The Week Dec 12 2014
    The rout was on, as major averages post worst weekly loss since 2012 Dec 12 2014
    Stocks Down In Afternoon; Caterpillar, Joy Global Hit Dec 12 2014
    Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe... Dec 11 2014
    Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe... Dec 11 2014
    JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 Dec 10 2014
    Stock Market Today: Wall Street Drops; Conn's Down 40% Dec 09 2014
    Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update Dec 09 2014
    Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update Dec 09 2014
    Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update Dec 09 2014
    Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update Dec 09 2014
    Top Global Stocks: Jazz, Actavis In IBD's World List Dec 08 2014
    Stocks Sink In Late Trading: Tesla, McDonald's Dive Dec 08 2014
    Stock Market Today: Indexes Close With Small Losses Dec 04 2014
    Jazz Pharmaceuticals (JAZZ) Starts Late-Stage Study on Xyrem Dec 03 2014
    Top Funds Gobble Up Tech And Medical Stocks Dec 02 2014
    Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic... Dec 02 2014
    Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem® (Sodium Oxybate)... Dec 02 2014
    Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic... Dec 02 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK